Sunlenca 300 mg film-coated tablets
*Company:
Gilead Sciences LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 22 October 2024
File name
Sunlenca Film coated tablets IE-XI SmPC (Sept 2024).pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 28 August 2024
File name
Sunlenca Tablets IE-XI PIL (July 2024).pdf
Reasons for updating
- Correction of spelling/typing errors
Updated on 28 August 2024
File name
Sunlenca Tablets IE-XI SmPC (July 2024).pdf
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 30 June 2023
File name
Sunlenca - Tablets - IE-XI SmPC (June 2023).pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 30 June 2023
File name
Sunlenca - Tablets - IE-XI PIL (June 2023).pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 21 October 2022
File name
Sunlenca - Tablets - IE-XI PIL (August 2022) - updated.pdf
Reasons for updating
- New PIL for new product
Updated on 21 October 2022
File name
Sunlenca - Tablets - IE-XI SmPC (August 2022) -updated.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)